Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 5/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011033 | 0.84 | ERN1 (0.36) | MEN1ALDH1A1KMT2AERN1KDM4E | |
| SCHEMBL275155 | 0.84 | KMT2A (0.40) | MEN1ALDH1A1KMT2ATDP1NFE2L2 | |
| SCHEMBL6066165 | 0.81 | KMT2A (0.39) | MEN1ALDH1A1KMT2ATDP1NFE2L2 | |
| Phosphine SCHEMBL6066159 | 0.81 | KMT2A (0.39) | MEN1ALDH1A1KMT2ATDP1NFE2L2 | |
| Hydrazine SCHEMBL5282146 | 0.79 | KMT2A (0.37) | MEN1ALDH1A1KMT2ATDP1NFE2L2 | |
| SCHEMBL4737965 | 0.74 | KDM4E (0.34) | MEN1ALDH1A1KMT2AERN1KDM4E | |
| SCHEMBL13946887 | 0.74 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2ATDP1ERN1 | |
| SCHEMBL678617 | 0.74 | EGFR (0.36) | MEN1ALDH1A1KMT2ATDP1NFE2L2 | |
| SCHEMBL14466190 | 0.74 | NFE2L2 (0.32) | MEN1ALDH1A1KMT2ATDP1NFE2L2 | |
| SCHEMBL13354648 | 0.71 | ERN1 (0.30) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987443-B2 | Processes and intermediates for making a JAK inhibitor | INCYTE CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987443-B2 | Processes and intermediates for making a JAK inhibitor | INCYTE CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | MEN1 1782/4885ALDH1A1 1529/4885KMT2A 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.